EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Immunogenicity and 1-year boostability of a three-dose intramuscular rabies pre-exposure prophylaxis schedule in adults receiving immunosuppressive monotherapy: a prospective single-centre clinical trial

Hannah M Garcia Garrido iD, Bridget van Put, Sanne Terryn iD, Cornelis A de Pijper, Cornelis Stijnis, Geert R D'Haens, Phyllis I Spuls, Marleen G van de Sande, Steven van Gucht, Martin P Grobusch, Abraham Goorhuis

Journal of Travel Medicine · 2023

DOI: 10.1093/jtm/taac148 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Travel Medicine, 2023. Verfasst von Hannah M Garcia Garrido und 10 weiteren Autor:innen. Beteiligte Einrichtung: Amsterdam UMC, Center for Tropical Medicine and Travel Medicine, Department of Infectious Diseases, University of Amsterdam, Amsterdam Institute for …. Hauptthemen laut MEDLINE: Rabies, Pre-Exposure Prophylaxis, Rabies Vaccines. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

For immunocompromised patients (ICPs), administration of rabies immunoglobulins (RIG) after exposure is still recommended regardless of prior vaccination, due to a lack of data. We aimed to assess the 1-year boostability of a three-dose rabies pre-exposure prophylaxis (PrEP) schedule in individuals using immunosuppressive monotherapy.

Methods

In this prospective study, individuals on immunosuppressive monotherapy with a conventional immunomodulator (cIM) or a TNF-alpha inhibitor (TNFi) for a chronic inflammatory disease received a three-dose intramuscular PrEP schedule (days 0,7,21–28) with 1 mL Rabipur®, followed by a two-dose simulated post-exposure prophylaxis (PEP) schedule (days 0,3) after 12 months. Rabies neutralizing antibodies were assessed at baseline, on day 21–28 (before the third PrEP dose), day 60, month 12 and month 12 + 7 days. The primary outcome was 1-year boostability, defined as the proportion of patients with a neutralizing antibody titre of ≥ 0.5 IU/mL at month 12 + 7 days. Secondary outcomes were geometric mean titres (GMTs) and factors associated with the primary endpoint.

Results

We included 56 individuals, of whom 52 completed the study. The 1-year boostability was 90% (47/52) with a GMT of 6.16 (95% CI 3.83–9.91). All participants seroconverted at some point in the study. Early response to PrEP (at day 21–28) was significantly associated with 100% boostability (Odds Ratio 51; 95% confidence interval [5.0–6956], P < 0.01). The vaccination schedule was safe and well tolerated. No vaccine-related serious adverse events occurred.

Conclusion

In patients using immunosuppressive monotherapy, a three-dose rabies PrEP schedule followed by a two-dose PEP schedule is immunogenic, with all patients seroconverting at some point in the study. Although boostability 7 days after PEP was not 100%, nobody would wrongly be denied RIG when only administered to those who responded early to PrEP while reducing the administration of RIG by 73%.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RabiesPre-Exposure ProphylaxisRabies VaccinesHumansAdultProspective StudiesAntibodies, ViralAntibodies, NeutralizingImmunosuppressive AgentsPost-Exposure ProphylaxisImmunization Schedule

Stichwörter der Autor:innen

boostabilityimmunocompromised hostpreexposure prophylaxisrabiesschedulevaccine

Substanzen

Antibodies, ViralAntibodies, NeutralizingImmunosuppressive AgentsRabies Vaccines

Autor:innen und Institutionen

  • Amsterdam UMC, Center for Tropical Medicine and Travel Medicine, Department of Infectious Diseases, University of Amsterdam, Amsterdam Institute for Infection and Immunity, Amsterdam 1081 HZ, The Netherlands.
  • Sciensano, Brussels 1050, Belgium.
  • Amsterdam UMC, Department of Gastroenterology, University of Amsterdam, Amsterdam 1081 HZ, The Netherlands.
  • Amsterdam UMC, Department of Dermatology, University of Amsterdam, Amsterdam 1081 HZ, The Netherlands.
  • Amsterdam UMC, Department of Rheumatology and Clinical Immunology, University of Amsterdam, Amsterdam 1081 HZ, The Netherlands.

ORCID-Profile: Hannah M Garcia Garrido, Sanne Terryn

Zitieren

APA

Garcia Garrido, H. M., van Put, B., Terryn, S., de Pijper, C. A., Stijnis, C., D'Haens, G. R., Spuls, P. I., van de Sande, M. G., van Gucht, S., Grobusch, M. P., & Goorhuis, A. (2023). Immunogenicity and 1-year boostability of a three-dose intramuscular rabies pre-exposure prophylaxis schedule in adults receiving immunosuppressive monotherapy: a prospective single-centre clinical trial. Journal of Travel Medicine. https://doi.org/10.1093/jtm/taac148

Vancouver

Garcia Garrido HM, van Put B, Terryn S, de Pijper CA, Stijnis C, D'Haens GR, et al. Immunogenicity and 1-year boostability of a three-dose intramuscular rabies pre-exposure prophylaxis schedule in adults receiving immunosuppressive monotherapy: a prospective single-centre clinical trial. Journal of Travel Medicine. 2023. doi:10.1093/jtm/taac148

BibTeX
@article{GarciaGarrido2023,
  author = {Garcia Garrido, Hannah M and van Put, Bridget and Terryn, Sanne and de Pijper, Cornelis A and Stijnis, Cornelis and D'Haens, Geert R and Spuls, Phyllis I and van de Sande, Marleen G and van Gucht, Steven and Grobusch, Martin P and Goorhuis, Abraham},
  title = {Immunogenicity and 1-year boostability of a three-dose intramuscular rabies pre-exposure prophylaxis schedule in adults receiving immunosuppressive monotherapy: a prospective single-centre clinical trial},
  journal = {Journal of Travel Medicine},
  year = {2023},
  doi = {10.1093/jtm/taac148}
}
Kostenlos starten →